Endothelial Dysfunction, Biomarkers, and Lung Function -Ancillary to MESA (MESA-LUNG)
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The purpose of MESA-Lung is to assess the role of endothelial dysfunction and genetic susceptibility in subclinical COPD.
| Condition |
|---|
|
Chronic Obstructive Pulmonary Disease (COPD) Emphysema Endothelial Dysfunction |
| Study Type: | Observational |
| Study Design: | Observational Model: Cohort Time Perspective: Prospective |
| Official Title: | Endothelial Dysfunction, Biomarkers, and Lung Function (MESA LUNG) |
- Lung Function [ Time Frame: 2004-2011 ] [ Designated as safety issue: No ]
- Lung Density [ Time Frame: 2000-2011 ] [ Designated as safety issue: No ]
| Enrollment: | 4359 |
| Study Start Date: | October 2004 |
| Estimated Study Completion Date: | November 2012 |
| Estimated Primary Completion Date: | November 2012 (Final data collection date for primary outcome measure) |
| Groups/Cohorts |
|---|
|
MESA Lung
MESA-Lung is an ancillary study of the Multi-Ethnic Study of Atherosclerosis (MESA). MESA, established in 1999, is well characterized, multi-ethnic (white, Black, Hispanic and Chinese), and multi-center (Columbia, Johns Hopkins, Northwestern, UCLA, Minnesota,and Wake Forest) prospective cohort study. MESA-Lung included a 60% random sample of the MESA cohort at the six Field Centers in Exam 3 and Exam 4, stratified on race/ethnicity.
|
Detailed Description:
Chronic obstructive pulmonary disease (COPD) is currently the fourth leading cause of death in the United States, and morbidity and mortality from COPD continue to rise. Despite the magnitude of the problem, therapeutic options are limited - particularly in comparison to cardiovascular disease. Smoking cessation is essential to the treatment and prevention of COPD. However, although smoking is the principal cause of COPD, only a minority of smokers develops symptomatic COPD and many former smokers develop COPD years to decades after they have stopped smoking. The only other medical intervention proven to reduce mortality from COPD is supplemental oxygen therapy. There is therefore an urgent need for newer understandings of the pathophysiology of COPD that might lead to the development of better therapies for COPD.
MESA-Lung is ancillary of the ongoing Multi-Ethnic Study of Atherosclerosis (MESA). MESA-lung will utilize the various existing measures of endothelial function that have been already been collected in MESA (flow-mediated dilatation [FMD] and related biomarkers and gene polymorphisms) to test the hypotheses that the endothelial dysfunction occurs in the clinical COPD.
Eligibility| Ages Eligible for Study: | 45 Years to 84 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
| Sampling Method: | Non-Probability Sample |
MESA cohort
Inclusion Criteria:
- A random sample of MESA participants active at Exam 3 and/or 4.
Exclusion Criteria:
- MESA participants without MESA Exam 3 or 4 measurements.
- MESA participants without FMD measurements in Exam 1.
- MESA participants who have not consented to genetic testing.
Contacts and Locations More Information
Additional Information:
Publications:
| Responsible Party: | Columbia University |
| ClinicalTrials.gov Identifier: | NCT00843271 History of Changes |
| Obsolete Identifiers: | NCT00094224 |
| Other Study ID Numbers: | AAAA7791, R01HL077612 |
| Study First Received: | February 12, 2009 |
| Last Updated: | January 12, 2012 |
| Health Authority: | United States: Institutional Review Board |
Keywords provided by Columbia University:
|
COPD MESA LUNG BIOMARKERS |
Additional relevant MeSH terms:
|
Emphysema Pulmonary Emphysema Lung Diseases Respiration Disorders |
Pulmonary Disease, Chronic Obstructive Lung Diseases, Obstructive Pathologic Processes Respiratory Tract Diseases |
ClinicalTrials.gov processed this record on May 21, 2013